Suppr超能文献

提高小儿终末期肝病评分对等待肝移植的幼儿的预测能力。

Improving the predictive ability of the pediatric end-stage liver disease score for young children awaiting liver transplant.

机构信息

Department of Pediatrics, University of Washington School of Medicine, Seattle Children's Hospital Center for Clinical and Translational Research, Seattle, Washington, USA.

Scientific Registry of Transplant Recipients, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.

出版信息

Am J Transplant. 2021 Jan;21(1):222-228. doi: 10.1111/ajt.15925. Epub 2020 May 29.

Abstract

The current pediatric end-stage liver disease (PELD) score underestimates pediatric waitlist mortality. Children frequently require PELD exception points to achieve appropriate priority ranking. We developed a new PELD score using serum sodium, creatinine, and updated original PELD components to more accurately rank children and equalize children's mortality risk with the age-standardized mortality rate of adults. We included children aged younger than 12 years with chronic liver disease, listed for deceased donor livers January 1, 2005-December 31, 2017. Pediatric candidates (n = 5111) were followed from listing to the earliest of waitlist mortality (death or removal from the list due to being too sick to undergo transplant, n = 339) or 180 days. We incorporated linear splines for the current components of PELD and added sodium and creatinine to the equation. The updated PELD-Na-Cr had a cross-validated AUC ROC of 0.854, vs 0.799 for the original PELD. PELD-Na-Cr required 9.44 additional points to equalize children's mortality risk with the age-standardized mortality rate of adults. PELD-Na-Cr better ordered the sickest children and should better prioritize children relative to adults. As a result, PELD-Na-Cr could increase pediatric transplant rates and reduce pediatric liver transplant waitlist mortality.

摘要

目前的儿科终末期肝病 (PELD) 评分低估了儿科等待名单上的死亡率。儿童通常需要 PELD 例外积分才能获得适当的优先排序。我们使用血清钠、肌酐和更新的原始 PELD 成分开发了一个新的 PELD 评分,以更准确地对儿童进行排名,并使儿童的死亡率风险与成人的年龄标准化死亡率相平衡。我们纳入了年龄在 12 岁以下、患有慢性肝病、于 2005 年 1 月 1 日至 2017 年 12 月 31 日接受已故供体肝脏移植的患者。儿科候选者(n=5111)从列入名单开始随访,直至最早出现等待名单死亡率(死亡或因病情太重而无法接受移植而从名单中删除,n=339)或 180 天。我们为 PELD 的当前成分纳入了线性样条,并在方程中添加了钠和肌酐。更新后的 PELD-Na-Cr 的交叉验证 AUC ROC 为 0.854,而原始 PELD 为 0.799。PELD-Na-Cr 需要额外的 9.44 分才能使儿童的死亡率风险与成人的年龄标准化死亡率相平衡。PELD-Na-Cr 更好地对病情最严重的儿童进行了排序,并且应该相对于成年人更好地对儿童进行优先排序。因此,PELD-Na-Cr 可以提高儿科移植率并降低儿科肝移植等待名单上的死亡率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验